KYTX
USDKyverna Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$6.670
Kõrge
$6.930
Madal
$6.670
Maht
0.31M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
291.5M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.57M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $31
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics with a Overweight and raises the price target from $27 to $31.
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics with a Buy and raises the price target from $10 to $20.
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
Seotud aktsiad
METCL
Ramaco Resources Inc. 9.00% Senior Notes due 2026
ORGO
Organogenesis Holdings Inc.
CRC
California Resources Corporation
PAA
Plains All American Pipeline L.P. Common Units representing Limited Partner Interests
JLS
Nuveen Mortgage and Income Fund
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.